S. aureus activates TNF signaling pathways PROJECT SUMMARY Staphylococcus aureus remains a major cause of human infection and the prevalence of invasive staphylococcal disease has increased in the past few years. Protein A or SpA is a highly conserved surface component of S. aureus that has multiple interactions with the immune system. Discrete domains of SpA activate TNFa signaling, EGFR-mediating responses and the activation of the type I interferon cascade. The SpA IgG binding domain activates TNFR1, an interaction that is central to the pathogenesis of pneumonia. We postulate that the SpA-TNFRI interaction is critical in staphylococcal invasion across mucosal barriers through its activation of RhoA GTPases that perturb actomyosin dynamics and disrupt epithelial tight junctions. The SpA IgG binding domain also is an EGFR ligand, stimulating its phosphorylation and activating the ADAM17 metallo-protease. We predict that EGFR also mediates the internalization of SpA, which, through its Xr domain, activates the type I interferon cascade, inducing epithelial production of IFN-b and Jak-STAT phosphorylation in a TLR4/TRIF-dependent fashion. Staphylococcal activation of type I interferons via the TLR4 cascade is postulated to have a major role in the pathogenesis of pneumonia and sepsis. As the Xr domain is a common site of in vivo mutation, duplication and deletion, we will determine if these mutations selected in vivo are generated specifically in response to immune pressure and establish how polymorphisms in Xr contribute to the virulence of S. aureus.
S. aureus activates TNF signaling pathways PROJECT NARRATIVE Staphylococcus aureus infection, especially MRSA infection, is a major public health problem causing increasing morbidity and mortality in previously healthy children and adults. This application focuses upon a major surface component of these bacteria, protein A, which has several important interactions with the immune responses of the host. We will establish the role of protein A in staphylococcal invasion across mucosal barriers as well as its ability to activate the type I interferon cascade in the lung. These studies will demonstrate how mutations in protein A have evolved to enhance the virulence of the organism and provide a potential target for therapeutic intervention.
Showing the most recent 10 out of 27 publications
